Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology.

To the Editor: We have read with great interest the recently published article by Gerber et al. ([1][1]) on the potential endometrial benefit of anastrozole given to postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology. Their study showed that the switch to anastrozole